The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

Cancer Research

Volumn 70, Issue 2, 2010, Pages 666-674

  Cerovac, Vesna ^a   Monteserin Garcia, Jose ^a   Rubinfeld, Hadara ^c   Buchfelder, Michael ^d   Losa, Marco ^e   Florio, Tullio ^f   Paez Pereda, Marcelo ^b   Stalla, Günter K ^a   Theodoropoulou, Marily ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Affectis Pharmaceutical AG   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; INSULIN RECEPTOR SUBSTRATE 1; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PHOSPHOTYROSINE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAPAMYCIN; S6 KINASE; SERINE; SOMATOSTATIN RECEPTOR; TRANSCRIPTION FACTOR E2F;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPOPHYSIS TUMOR; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

ADENOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; OCTREOTIDE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PITUITARY NEOPLASMS; SIROLIMUS; UP-REGULATION;

EID: 76549120195     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2951     Document Type: Article

References (51)

1. Leslie NR, Biondi RM, Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev 2001;101: 2365-80.
2. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11:701-13.
3. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2009;2:339-45.
4. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
5. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10: 594-601.
6. Huang S, Bjornsti MA, Houghton PJ. Rapamycins - mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-32.
7. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
8. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200-5.
9. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000;14:783-94.
10. Paz K, Liu YF, Shorer H, et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 1999;274:28816-22.
11. Mothe I, VanObberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem 1996;271:11222-7.
12. Sun SY, Rosenberg LM, Wang XR, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
13. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-40.
14. Bousquet C, Guillermet-Guibert J, Saint-Laurent N, et al. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 2006;25:3943-54.
15. Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006;66:1576-82.
16. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002;13:451-7.
17. Renner U, Brockmeier S, Strasburger CJ, et al. Growth-hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells - interaction with GH-releasing hormone, thyrotropin-releasing-hormone, and octreotide. J Clin Endocrinol Metab 1994;78:1090-6.
18. Florio T, Barbieri F, Spaziante R, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 2008;15: 583-96.
19. Paez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001;108:1123-31.
20. Gorshtein A, Rubinfeld H, Kendler E, et al. mTOR inhibitors rapamycin and RAD001 (everolimus) induce antiproliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009;16: 1017-27.
21. Pagotto U, Arzberger T, Theodoropoulou M, et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 2000;60:6794-9.
22. Paez-Pereda M, Giacomini D, Refojo D, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci U S A 2003;100:1034-9.
23. Pages P, Benali N, Saint-Laurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1) - evidence for the role of SHP-1. J Biol Chem 1999;274:15186-93.
24. Andjelkovic M, Alessi DR, Meier R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997;272: 31515-24.
25. Musat M, Korbonits M, Kola B, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005;12:423-33.
26. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell-cycle regulators of proliferation in vascular smooth-muscle cells. Circ Res 1995;76:412-7.
27. 1 cell-cycle block. Endocrinology 1995; 136:4174-81.
28. Srikant CB. Cell-cycle dependent induction of apoptosis by somatostatin analog SMS-201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 1995;209:400-6.
29. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
30. Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-Cdk2 complex during the G(1)-phase of the human cell-cycle. Science 1992;257:1689-94.
31. Schwarz JK, Devoto SH, Smith EJ, Chellappan SP, Jakoi L, Nevins JR. Interactions of the P107 and Rb proteins with E2F during the cell-proliferation response. EMBO J 1993;12:1013-20.
32. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001;142:121-8.
33. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27(Kip1) cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
34. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996;137:3051-60.
35. Rocchi S, Tartaredeckert S, Mothe I, VanObberghen E. Identification by mutation of the tyrosine residues in the insulin-receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinase. Endocrinology 1995;136:5291-7.
36. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser(2481) is a marker for intact mTOR signaling complex 2. Cancer Res 2009;69: 1821-7.
37. Florio T, Thellung S, Arena S, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999;141:396-408.
38. Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 2002;5:89-98.
39. Chanson P, Brochier S. Non-functioning pituitary adenomas. J Endocrinol Invest 2005;28:93-9.
40. Tichomirowa MA, Daly AF, Beckers A. Treatment of pituitary tumors: somatostatin. Endocrine 2005;28:93-100.
41. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
42. 1 of an osteosarcoma cell line. J Biol Chem 1993;268:22825-9.
43. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G(1) to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273:14424-9.
44. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70(s6K) pathway in human pancreatic cancer cells. Cancer Res 1999;59:3581-7.
45. 1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268:3734-8.
46. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T-lymphocytes. J Biol Chem 1993; 268:22737-45.
47. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006;24:185-97.
48. Dong JJ, Peng JY, Zhang HX, et al. Role of glycogen synthase kinase 3β in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 2005;65:1961-72.
49. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26: 4311-8.
50. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bemstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008;15:257-66.
51. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008;87:168-81.